Phenytoin (Dilantin)

Phenytoin, commonly known by the brand name Dilantin, is an anticonvulsant medication belonging to the hydantoin class of drugs that has been used in equine medicine for the management of seizure disorders. Originally developed for human epilepsy treatment in the 1930s, phenytoin represents one of the oldest and most studied anticonvulsant medications available. In horses, this medication is used on an off-label basis to control seizures and certain types of cardiac arrhythmias, though its use in equine patients is considerably less common than in human medicine due to the availability of other anticonvulsant options and the unique pharmacokinetic challenges presented by equine patients.

The mechanism of action of phenytoin involves stabilization of neuronal membranes by blocking voltage-gated sodium channels. This action prevents the repetitive firing of action potentials that characterizes seizure activity. By reducing the spread of abnormal electrical activity in the brain, phenytoin helps prevent seizures from occurring or reduces their severity when they do occur. The medication also has membrane-stabilizing effects on cardiac tissue, which explains its occasional use for certain cardiac arrhythmias in horses. The duration of action can be variable in equine patients due to differences in metabolism compared to other species.

Phenytoin is available in several formulations including oral tablets, oral suspension, and injectable solution for intravenous administration. In horses, the oral forms are most commonly used for maintenance therapy, while intravenous administration may be employed for acute seizure management or when rapid drug levels are needed. The medication can be administered by mixing with feed, though palatability may be an issue for some horses. Injectable phenytoin must be administered carefully as it is highly alkaline and can cause tissue damage if given outside the vein. The frequency of dosing in horses often needs to be higher than in humans due to more rapid metabolism.

The safety profile of phenytoin in horses requires careful consideration, as this medication has a narrow therapeutic index meaning the difference between effective and toxic doses is relatively small. Regular monitoring of blood levels is recommended when possible to ensure adequate seizure control while minimizing the risk of toxicity. Veterinary supervision is essential throughout treatment, and owners should be educated about the signs of both inadequate seizure control and potential drug toxicity. Completing the prescribed treatment course and maintaining consistent dosing schedules is crucial for effective seizure management in equine patients.

The primary indication for phenytoin use in horses is the management of seizure disorders, including epilepsy and status epilepticus. Seizures in horses, while relatively uncommon compared to other species, can result from various underlying causes including head trauma, infectious diseases affecting the central nervous system, metabolic disturbances, toxin exposure, and idiopathic epilepsy. Phenytoin may be considered as part of a comprehensive seizure management protocol when other first-line anticonvulsants have proven ineffective or are contraindicated. The medication is particularly valuable in cases where long-term seizure control is needed and the horse has not responded adequately to more commonly used equine anticonvulsants.

In managing seizure disorders, phenytoin works to reduce both the frequency and severity of seizure episodes. The medication is most effective for focal seizures and generalized tonic-clonic seizures, though response can vary among individual horses. Horses with idiopathic epilepsy may require lifelong anticonvulsant therapy, and phenytoin represents one option in the veterinarian's treatment arsenal. The medication may be used alone or in combination with other anticonvulsants depending on the severity of the seizure disorder and the individual patient's response to treatment. Expected outcomes include reduced seizure frequency, shorter seizure duration, and faster post-ictal recovery.

Secondary uses for phenytoin in equine medicine include management of certain cardiac arrhythmias, particularly those induced by digitalis toxicity or other causes of ventricular irritability. The membrane-stabilizing properties of phenytoin make it useful for controlling abnormal cardiac electrical activity in select cases. This application represents a highly specialized use that would typically be employed in referral hospital settings under close cardiac monitoring. Veterinarians may choose phenytoin for arrhythmia management when other antiarrhythmic medications have not provided adequate control or are contraindicated.

Additional clinical applications for phenytoin in horses may include management of myotonia, a condition characterized by delayed muscle relaxation after contraction. Some horses with inherited or acquired myotonic disorders may benefit from phenytoin's sodium channel blocking effects, which can help reduce the abnormal muscle activity characteristic of this condition. The medication has also been investigated for use in managing certain types of chronic pain conditions in horses, though this application remains largely experimental and is not a primary indication.

The selection of phenytoin over other anticonvulsant options depends on several factors including the specific type of seizure disorder, previous treatment history, the need for combination therapy, and practical considerations such as ease of administration and monitoring requirements. Phenytoin may be chosen when other medications have failed to provide adequate seizure control, when its particular pharmacological profile offers advantages for a specific patient, or when cardiac arrhythmia management is a concurrent concern. Cost considerations and the availability of therapeutic drug monitoring may also influence the decision to use phenytoin in equine patients.

Dosing of phenytoin in horses requires careful individualization by the attending veterinarian, as equine patients demonstrate considerable variability in their metabolism of this medication. The general approach to phenytoin therapy involves starting with a loading dose to achieve therapeutic blood levels quickly, followed by maintenance dosing to sustain those levels. Due to the narrow therapeutic index of phenytoin, dosing must be precise and based on accurate body weight estimation. Horses range dramatically in size from miniatures at 150-350 pounds to draft breeds exceeding 2,000 pounds, making weight-based dosing calculations essential. Whenever possible, obtaining an accurate weight using a scale rather than a weight tape provides the most reliable basis for dosing.

Typical dosing guidelines for phenytoin in horses involve initial loading doses followed by maintenance therapy, though specific protocols vary based on the clinical situation and individual patient factors. Loading doses, when used, are typically divided and administered over several hours to reduce the risk of adverse effects associated with rapid intravenous administration. Maintenance doses are generally administered multiple times daily due to the relatively rapid metabolism of phenytoin in horses compared to humans and small animals. The maximum daily dose must be carefully considered to avoid toxicity, and therapeutic drug monitoring is strongly recommended to optimize dosing for each individual patient.

Treatment duration with phenytoin depends entirely on the underlying condition being managed. For horses with idiopathic epilepsy, lifelong therapy may be necessary to maintain seizure control. In cases where seizures result from an acute, treatable underlying cause, phenytoin therapy may be temporary until the primary condition resolves. The response to treatment should be evaluated regularly, with adjustments to dosing made based on seizure frequency, side effect profile, and when available, serum drug concentrations. Veterinary follow-up is essential to assess treatment efficacy and make necessary modifications.

Administration of oral phenytoin to horses can be accomplished through several methods. Tablets or capsules may be crushed and mixed with a small amount of palatable feed or administered as a slurry via oral syringe. The oral suspension formulation may be easier to administer to some horses. Phenytoin should generally be given consistently with respect to feeding, as food can affect absorption. Some practitioners recommend administering the medication on an empty stomach or at least 30 minutes before feeding to optimize absorption, while others find that administration with a small amount of grain improves palatability without significantly affecting drug levels. Consistency in the timing and method of administration is more important than the specific approach chosen.

If a dose of phenytoin is missed, the appropriate response depends on how much time has passed and the stability of the patient's seizure control. For horses on maintenance therapy who miss a single dose, the missed dose may be given if remembered within a few hours, or the regular dosing schedule may simply be resumed if the missed dose is not remembered until close to the next scheduled dose. Doubling up on doses should never be done, as this significantly increases the risk of toxicity. Owners should be instructed to contact their veterinarian if doses are missed, particularly if seizure activity increases or if multiple doses have been missed.

Completing the prescribed course of phenytoin therapy is essential for effective seizure management. Unlike antibiotics where premature discontinuation leads to treatment failure, abrupt discontinuation of anticonvulsants like phenytoin can precipitate seizure activity, potentially including severe or life-threatening status epilepticus. If discontinuation of phenytoin is desired, this should be done under veterinary supervision with a gradual tapering schedule. The decision to modify or discontinue therapy should be based on clinical response, side effect profile, and the underlying cause of seizures, and should always involve the treating veterinarian.

Phenytoin is generally tolerated by horses when dosed appropriately, though like all anticonvulsant medications, it carries potential for adverse effects that owners and caregivers should understand. The narrow therapeutic index of phenytoin means that side effects become increasingly likely as blood levels approach the upper end of the therapeutic range or exceed it. Close monitoring during treatment initiation and ongoing therapy helps identify side effects early so that dosing adjustments can be made before more serious complications develop. Most horses on well-managed phenytoin therapy experience minimal side effects that do not significantly impact their quality of life.

Common and generally mild side effects of phenytoin in horses may include sedation or lethargy, particularly during the initial period of treatment or after dose increases. Some horses exhibit changes in appetite, either decreased interest in food or alterations in eating behavior. Mild gastrointestinal effects such as soft stools or changes in manure consistency may occur. Incoordination or ataxia can be seen at higher blood levels and often indicates the need for dose reduction. These effects are typically dose-related and often improve with time as the horse adjusts to the medication or with appropriate dose modifications.

Moderate side effects requiring veterinary attention include significant ataxia or incoordination that affects the horse's ability to move safely, pronounced sedation that interferes with normal activities, persistent gastrointestinal upset including decreased appetite or colic signs, and behavioral changes such as unusual aggression or depression. Hepatic effects are a particular concern with phenytoin therapy, and monitoring liver enzymes periodically is recommended for horses on long-term treatment. Signs of liver dysfunction may include jaundice, decreased appetite, weight loss, or changes in manure color. Any of these symptoms warrant prompt veterinary evaluation.

Serious side effects of phenytoin that require immediate veterinary attention include severe neurological signs such as profound ataxia, recumbency, or paradoxical increase in seizure activity. Cardiovascular effects including arrhythmias or signs of cardiovascular compromise warrant emergency evaluation. Severe allergic reactions, though uncommon, may manifest as hives, facial swelling, difficulty breathing, or collapse. Signs of severe liver toxicity including marked jaundice, bleeding tendencies, or neurological changes consistent with hepatic encephalopathy constitute emergencies. Intravenous phenytoin that extravasates outside the vein can cause severe tissue necrosis requiring immediate intervention.

Rare side effects associated with phenytoin include gingival hyperplasia, which has been well-documented in humans and dogs on long-term therapy but appears less common in horses. Hematological effects including decreased white blood cell or platelet counts can occur rarely and may manifest as increased susceptibility to infection or unexplained bleeding or bruising. Skin reactions ranging from mild rashes to severe conditions have been reported in other species. Long-term use concerns include the potential for bone mineral density changes and effects on vitamin D metabolism. Owners should contact their veterinarian if any unusual signs develop during phenytoin therapy, even if they seem unrelated to the medication, as phenytoin can affect multiple body systems.

The most absolute contraindication to phenytoin use is known hypersensitivity or previous allergic reaction to phenytoin or other hydantoin medications. Horses that have experienced allergic reactions to phenytoin should never receive the medication again, as subsequent reactions may be more severe. Cross-reactivity with other hydantoin compounds means that horses allergic to phenytoin may also react to related medications. Before initiating phenytoin therapy, veterinarians should inquire about any previous adverse reactions to anticonvulsant medications. The importance of disclosing complete medication history to the veterinarian cannot be overstated.

Hepatic dysfunction represents a significant contraindication or at minimum a strong caution for phenytoin use. The liver is the primary site of phenytoin metabolism, and horses with compromised liver function may accumulate dangerous drug levels even at standard doses. Additionally, phenytoin itself can cause hepatotoxicity, potentially worsening existing liver disease. Horses with known liver disease, elevated liver enzymes, or other indicators of hepatic compromise require careful evaluation before phenytoin therapy is considered. If phenytoin must be used in these patients, dose reductions and intensive monitoring are essential. Alternative anticonvulsants with less hepatic impact may be preferred in horses with liver concerns.

Considerations regarding life stage significantly impact phenytoin use decisions. The safety of phenytoin in pregnant mares has not been established, and the medication crosses the placenta with potential for fetal effects. In humans, phenytoin is associated with fetal abnormalities, raising concerns about use during equine pregnancy. Nursing mares present similar concerns as phenytoin appears in milk and could affect the foal. Use in very young foals requires extreme caution due to immature metabolic capacity that may result in prolonged drug effects and increased toxicity risk. Geriatric horses may also require dose adjustments due to age-related changes in liver function and drug metabolism. Breeding stallions should be evaluated individually, though direct effects on fertility are not well documented in horses.

Other medical conditions may contraindicate or require extreme caution with phenytoin therapy. Horses with cardiac conduction abnormalities, particularly those involving the sinoatrial or atrioventricular nodes, may experience worsening of these conditions with phenytoin. Horses with blood dyscrasias or bone marrow suppression are at increased risk for hematological side effects. Conditions affecting drug absorption such as severe gastrointestinal disease may result in unpredictable blood levels. Competition horses present special considerations due to phenytoin's classification as a controlled medication by most regulatory bodies, making its use potentially problematic for horses intended to compete. The lengthy detection time of phenytoin means that even therapeutic use may result in competition violations.

Phenytoin is notable for its extensive drug interaction profile, which stems from its complex hepatic metabolism and effects on drug-metabolizing enzymes. Major interactions that represent potentially serious or life-threatening risks include concurrent use with other central nervous system depressants, which can result in profound sedation, respiratory depression, and cardiovascular effects. The combination of phenytoin with certain other anticonvulsants requires careful management, as interactions can be unpredictable, sometimes increasing and sometimes decreasing blood levels of one or both drugs. Concurrent administration of phenytoin with medications that strongly inhibit or induce liver enzymes can dramatically alter phenytoin blood levels, potentially leading to toxicity or loss of seizure control.

Moderate interactions requiring careful monitoring include phenytoin's effects on corticosteroid metabolism. Phenytoin induces the liver enzymes responsible for metabolizing corticosteroids, potentially reducing their effectiveness. This interaction is clinically significant when horses are receiving both medications, as it may necessitate higher corticosteroid doses to achieve the desired effect. Conversely, discontinuing phenytoin in a horse receiving corticosteroids may lead to corticosteroid excess. Other drugs whose metabolism may be affected by phenytoin's enzyme-inducing properties include certain antimicrobials, antiparasitic medications, and other drugs metabolized by the cytochrome P450 system. Phenytoin blood levels themselves can be altered by numerous medications that affect its metabolism.

Interactions with supplements and feed components deserve consideration in equine patients. Calcium-containing supplements or feeds high in calcium may interfere with phenytoin absorption when given concurrently. Enteral feeding products can reduce phenytoin absorption significantly. Some herbal supplements may interact with phenytoin through enzyme induction or inhibition, though specific data in horses is limited. Timing of phenytoin administration relative to feeding and supplements can help minimize some of these interactions. Veterinarians should be informed of all supplements, including joint supplements, calming products, and herbal preparations, when designing a phenytoin treatment protocol.

Competition and performance horse considerations regarding drug interactions extend to the cumulative effect of multiple medications on withdrawal times and detection. Phenytoin itself is typically prohibited in competition, but even in non-competing horses, interactions with other commonly used medications must be considered. Concurrent use of multiple medications metabolized by the liver can complicate phenytoin management and increase the risk of adverse effects. Horses requiring sedation for procedures while on phenytoin therapy may require dose adjustments of sedative medications. The importance of veterinary guidance for any horse on phenytoin therapy receiving additional medications cannot be overemphasized, as even seemingly routine treatments may interact significantly with this anticonvulsant.

Monitoring requirements for horses on phenytoin therapy are substantial due to the narrow therapeutic index and complex pharmacokinetics of this medication. Baseline blood work including complete blood count and serum chemistry panel with liver enzymes should be obtained before initiating therapy whenever possible. Therapeutic drug monitoring to assess phenytoin blood levels is highly recommended, particularly during treatment initiation, after dose changes, and periodically during maintenance therapy. Clinical monitoring for signs of toxicity including ataxia, sedation, and behavioral changes should be ongoing. Liver enzyme monitoring at regular intervals during long-term therapy helps detect hepatotoxicity early. The frequency of monitoring depends on the stability of the patient and the duration of therapy.

Special populations require additional precautions when phenytoin therapy is considered. Foals and young horses have immature metabolic capacity and may process phenytoin differently than adult horses, requiring dose modifications and closer monitoring. Geriatric horses may have declining liver and kidney function that affects phenytoin metabolism and excretion. Pregnant mares present ethical and medical concerns given the potential for fetal effects, and phenytoin should generally be avoided during pregnancy unless the benefits clearly outweigh the risks. Lactating mares on phenytoin therapy may expose nursing foals to the medication through milk. Horses with chronic diseases affecting the liver, kidneys, or heart require individualized risk-benefit assessment before phenytoin therapy.

Competition and performance horse considerations are critical for phenytoin, as this medication is classified as a prohibited substance by virtually all equine regulatory bodies including the FEI, USEF, and racing commissions. The detection time for phenytoin can be prolonged, meaning that even discontinued therapy may result in positive tests for extended periods. There is no circumstance under which phenytoin would be permissible for use in horses competing under most regulatory frameworks. Horses transitioning from phenytoin therapy to competition careers require careful planning with extended withdrawal periods and potentially confirmatory testing before competing. Owners and trainers must understand that phenytoin use and competition are incompatible, and they should maintain detailed medication records.

Administration precautions include proper handling of injectable phenytoin, which is highly alkaline and can cause severe tissue damage if administered outside the vein. Intravenous injection must be performed carefully by experienced personnel, with attention to maintaining proper catheter placement throughout the injection. Oral formulations should be stored and handled according to manufacturer recommendations. Human exposure to phenytoin should be minimized, particularly for pregnant women who should avoid handling the medication due to its teratogenic potential. Proper disposal of unused medication and containers prevents environmental contamination and accidental exposure.

Long-term use considerations for phenytoin include the potential for cumulative toxicity, development of tolerance requiring dose adjustments, and the importance of ongoing monitoring for hepatic effects. Horses on chronic phenytoin therapy should have periodic veterinary evaluations including physical examination and appropriate laboratory monitoring. The goal of long-term therapy should be assessed periodically, with consideration of whether continued treatment is necessary and whether alternative approaches might offer advantages. Abrupt discontinuation of phenytoin after long-term use can precipitate seizure activity, including potentially life-threatening status epilepticus, so any discontinuation should be gradual and medically supervised.

Proper storage of phenytoin is essential to maintain medication stability and effectiveness throughout its shelf life. Oral formulations should be stored at controlled room temperature, typically between 68-77 degrees Fahrenheit (20-25 degrees Celsius), with brief excursions permitted in the 59-86 degree Fahrenheit range. The medication should be protected from light, making storage in original containers or light-resistant packaging important. Humidity can affect some phenytoin formulations, so storage in dry conditions away from bathroom medicine cabinets or humid barn environments is recommended. Injectable phenytoin may have different storage requirements including refrigeration for some formulations, and manufacturer guidelines should be followed specifically. Tack room or barn storage is acceptable if temperature and humidity conditions can be maintained within appropriate ranges.

Safe handling practices for phenytoin protect both humans and horses during medication administration. Personnel administering phenytoin should wash hands thoroughly before and after handling the medication. Pregnant women should avoid handling phenytoin due to its teratogenic potential in humans, and if handling is necessary, gloves should be worn. Crushing tablets for oral administration should be done carefully to minimize dust inhalation, ideally in a well-ventilated area or using containment measures. Spillage should be cleaned up promptly using appropriate methods. Injectable phenytoin requires careful handling to avoid extravasation, and personnel should be trained in proper intravenous administration technique. Accidental human exposure to injectable phenytoin, particularly extravasation, requires immediate medical attention.

Expiration dating must be respected for phenytoin products, as degradation can occur over time potentially affecting both efficacy and safety. The manufacturer's expiration date should be clearly noted at the time of dispensing, and medication should not be used beyond this date. Signs of degradation in oral preparations may include changes in color, consistency, or odor, while injectable solutions should be inspected for particulate matter or discoloration before each use. Disposal of expired phenytoin should be handled through appropriate pharmaceutical waste channels rather than household trash or drain disposal to prevent environmental contamination and accidental exposure. Many veterinary clinics and human pharmacies offer medication disposal programs. Never use expired phenytoin, as both reduced efficacy potentially leading to breakthrough seizures and altered toxicity profiles are concerns.

Draft horses including Clydesdales, Percherons, Shires, and Belgians present specific considerations for phenytoin therapy related to their large body mass and potentially different metabolic characteristics. Accurate weight determination is critical in these breeds, as draft horses can weigh well over 2,000 pounds, and underestimation of weight may result in inadequate dosing while overestimation increases toxicity risk. The relatively higher body mass to surface area ratio may affect drug distribution and clearance. Draft breeds may require more frequent dosing intervals or higher total daily doses to maintain therapeutic blood levels, though this should be determined through therapeutic drug monitoring rather than assumed. Feathering on draft horses' legs does not affect phenytoin therapy but may be relevant for owners assessing overall health status during treatment.

Light horses and warmbloods represent the typical equine patient population for phenytoin therapy. Standard dosing guidelines, when available, are generally developed with these breeds in mind. Performance horse considerations are particularly relevant in these breeds, as many light horses and warmbloods participate in competitive activities where phenytoin is prohibited. Breed-specific neurological conditions may influence the decision to use phenytoin. Warmbloods have increased prevalence of certain conditions that may indirectly affect treatment decisions. Thoroughbreds and other hot-blooded breeds may demonstrate different behavioral responses to sedative effects of phenytoin compared to calmer breeds.

Ponies and miniature horses require particular attention to dosing precision due to their small body size. A dosing error that might be tolerable in a 1,200-pound horse could result in significant overdose in a 300-pound pony. These breeds also have increased prevalence of metabolic conditions including Equine Metabolic Syndrome and pituitary pars intermedia dysfunction, which may affect overall health status and potentially influence phenytoin metabolism. The concentration of oral preparations must be carefully considered when dosing small equines to allow for accurate measurement of small doses. Miniature horses may be particularly susceptible to the sedative effects of phenytoin, and careful monitoring during treatment initiation is warranted.

Breed-specific genetic conditions may influence phenytoin therapy decisions. Quarter Horses and related breeds should be evaluated for HYPP status if not already known, as seizure-like episodes in these horses may actually represent hyperkalemic events requiring different treatment approaches. Arabian horses with certain genetic conditions affecting the nervous system present diagnostic challenges that should be resolved before committing to long-term anticonvulsant therapy. While phenytoin itself has no known breed-specific contraindications, the accurate diagnosis of the underlying seizure disorder is essential before therapy begins. Veterinarians should consider the full spectrum of breed-related conditions when evaluating a horse presenting with seizure activity.

Alternative anticonvulsants within the same pharmacological approach include other medications that work through sodium channel blockade or similar mechanisms. Potassium bromide represents the most commonly used anticonvulsant in equine practice and may be preferred over phenytoin for many horses due to its longer half-life, wider therapeutic index, and established use in equine patients. Zonisamide is a newer anticonvulsant that has seen increasing use in veterinary medicine and may offer advantages in some patients. Other human anticonvulsants including levetiracetam, gabapentin, and pregabalin have been used in horses with varying success. The choice among these alternatives depends on the specific seizure disorder, patient factors, availability of therapeutic monitoring, and previous treatment history.

Different pharmacological classes may be considered when seizures are refractory to sodium channel blockers or when the mechanism of seizures suggests alternative approaches. Benzodiazepines including diazepam are commonly used for acute seizure management and status epilepticus in horses but are less practical for long-term maintenance therapy. Phenobarbital, while widely used in small animals, presents challenges in horses due to regulatory concerns as a controlled substance and its classification as prohibited in competition. For horses with seizures secondary to specific underlying conditions, treating the primary cause may reduce or eliminate the need for anticonvulsant therapy. Consultation with a veterinary neurologist may be beneficial for horses with refractory seizures.

Complementary approaches to seizure management in horses may include environmental and management modifications to reduce seizure triggers when identifiable. Stress reduction, maintaining consistent routines, and avoiding known precipitating factors can support pharmacological therapy. Nutritional support including ensuring adequate magnesium and electrolyte balance may be beneficial in some cases. Physical therapy and rehabilitation may be appropriate for horses recovering from seizure-related injuries. The importance of veterinary guidance when considering alternative or complementary approaches cannot be overstated, as inappropriate discontinuation of effective anticonvulsant therapy can have serious consequences. Any changes to a seizure management protocol should be made under veterinary supervision.